Global Prurigo Nodularis Treatment Market Set to Expand, Reaching USD 930.9 Million by 2033 Growing at a 3.0% CAGR

Prurigo Nodularis Treatment Market
Prurigo Nodularis Treatment Market

The global prurigo nodularis treatment market is poised for substantial growth, projected to reach a valuation of USD 693.3 million by 2023, according to a recent report by Future Market Insights. The market is anticipated to expand at a compound annual growth rate (CAGR) of 3.0% from 2023 to 2033, potentially reaching USD 930.9 million by the end of the forecast period.

Prurigo nodularis, a rare and debilitating skin condition, has prompted significant advancements in orphan drug development. Regulatory bodies have implemented favorable measures to accelerate the development and approval processes for drugs targeting rare diseases. These initiatives are expected to catalyze the expansion of the prurigo nodularis treatment market.

Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-3339

Key Takeaways from the Market Study:

  • Global prurigo nodularis treatment market grew at a CAGR of 2.8% between 2017 and 2022.
  • Europe prurigo nodularis treatment market accounted for a revenue share of 58.6% in 2022.
  • Germany is expected to dominate the regional market by growing at a CAGR of 5.1% during the forecast period.
  • North American prurigo nodularis market accounted for a revenue share of 14.9% in 2022.
  • Japan is considered to be among the most developed nations raising the share of the market with a value of 4.0%
  • Growth in the economy for prurigo nodularis treatment has led to colossal growth in China market at a CAGR of 3.6%
  • Capsacin cream segment dominated the prurigo nodularis treatment market by accounting for a revenue share of 40.34% in 2022.
  • Retail pharmacies accounted for a revenue share of 53.10% in 2022, in the prurigo nodularis treatment market.

Innovations in new treatment options and increasing demand for capsaicin cream are the prominent drivers to raise the market growth of the Prurigo Nodularis Treatment”, says comments a Future Market Insights Analyst.

Customization Available Request: https://www.futuremarketinsights.com/customization-available/rep-gb-3339

Competitive Landscape:

Some of the prominent players in the global market are-

  • Bayer AG
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Celgene Corporation
  • Galderma SA (Nestle Skin Health Company)
  • VYNE Therapeutics Inc.

Some of the important developments of the key players in the market are:

  • In June 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from an interim analysis of Cohort 1 of the Phase 3 THOR study, evaluating treatment with BALVERSA® (erdafitinib) versus chemotherapy in patients with metastatic or unresectable urothelial carcinoma (UC) and selected fibroblast growth factor receptor (FGFR) gene alterations who had received prior treatment with an anti-programmed death ligand 1 (PD-[L]1) agent.
  • The study met its primary endpoint of overall survival (OS) and reduced the risk of death by 36 percent. 1 Following the accelerated approval of BALVERSA® in 2019, these confirmatory data were featured in a Late-Breaking Presentation Session (Abstract # LBA4619) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Segmentation:

By Drug Class:

  • Corticosteroids
    • Topical
    • Oral
    • Emollients
    • Capsaicin Cream
    • Antihistamines
    • Anticonvulsants
    • Antidepressants
    • Neurokinin 1 Receptor (NK1R)
    • Opiate Receptor Antagonists
    • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East & Africa

Full Report Revealed: https://www.futuremarketinsights.com/checkout/3339

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these